UNSPSC 51386016: Tenosiprol

This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3E44064G8N. European Medicines Agency schedules Tenosiprol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10899MIG. Tenosiprol generally arises in the molecular formula C10H11NO4S.

UNSPSC 51386016 Tenosiprol, a Commodity code, shows minimal recent activity aligned with its nominal pharmaceutical scope. The single recent state-local opportunity tagged under this code—Seminole County, Florida's IFB for naloxone and drug deactivation systems—does not match tenosiprol procurement. State and local governments buying under this code, when opportunities surface, are purchasing specific pharmaceutical products for community health and emergency response programs. Seminole County's procurement reflects a broader pattern in which local health departments and county governments use UNSPSC pharmaceutical codes to solicit injectable and life-safety medications, though the county's current IFB describes naloxone and drug deactivation systems rather than tenosiprol specifically.

Seminole County, Florida remains the only recent issuing body visible in the available opportunities dataset. The county posted IFB 60459723LAS on June 30, 2026, with a response deadline of July 26, 2023, seeking annual delivery of 1,900 units of naloxone and 800 safe drug deactivation systems to the Seminole County Community Health Building at 520 W. Lake Mary Blvd, Sanford, Florida. The contract includes a two-year initial term with a one-year renewal option and requires quarterly deliveries, electronic bid submission, drug-free workplace certification, E-Verify compliance, and standard commercial insurance. The procurement does not name explicit set-asides and may be funded through FEMA. Beyond this single opportunity, the code shows no recent state-local contract activity in the available dataset, suggesting either limited demand for tenosiprol procurement through state and local channels or misclassification of related pharmaceutical solicitations under other codes.